A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for ...

This latest approval in combination with pembrolizumab marks another step forward ... Congress and were published in the New England Journal of Medicine. Padcev (enfortumab vedotin) is a ...

Published in the New England Journal of Medicine, researchers at University ... which include durvalumab and enfortumab vedotin combined with pembrolizumab, are presenting game-changing benefits ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Tirzepatide is a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors that results in 12 to 21% weight loss in patients with obesity; however ...

Published in the New England Journal of Medicine, researchers at University ... which include durvalumab and enfortumab vedotin combined with pembrolizumab, are presenting game-changing benefits ...

For over 200 years, the New England Journal of Medicine (NEJM) has brought important medical news to the world’s most influential physicians. The global medical community, physicians ...

MSD's powerhouse PD-1 inhibitor Keytruda (pembrolizumab ... which has been published in the New England Journal of Medicine. The drug has previously been cleared in the UK, Switzerland, and ...